Volume 132, Issue 13



September 27, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Signaling properties of G6b-B required for platelet production. See the article by Hofmann et al.

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
In a plenary paper, Pengo and colleagues demonstrate that rivaroxaban is inferior to warfarin for the prevention of thromboembolic events, major bleeding, and vascular death in patients with high-risk antiphospholipid antibody syndrome in a randomized, multicenter, controlled study.

Making HSCs in vitro: don’t forget the hemogenic endothelium
This Blood Spotlight presents a comprehensive discussion of the emerging developments of the generation of hematopoietic stem cells (HSCs) from human pluripotent stem cells.

Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice


Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis
These articles describe the signal transducing properties of G6b-B that are required for normal platelet production by megakaryocytes in both humans and mice.

Cooperative PSGL-1 and CXCR2 signaling in neutrophils promotes deep vein thrombosis in mice
This study reports the mechanism by which neutrophils adhere to activated endothelium and enhance murine venous thrombosis through formation of neutrophil extracellular traps.

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies
This article presents a multicenter phase 2 trial of reduced intensity conditioning with alemtuzumab for allogeneic hematopoietic stem cell transplantation for children with hemophagocytic lymphohistiocytosis (HLH) and other forms of primary immune deficiency. The results offer a reference standard for survival and safety, informing future approaches aimed at improving engraftment and long-term outcome.

Acute hyperviscosity: syndromes and management
This Review Article examines the biology, clinical manifestations, and treatment of acute hyperviscosity syndromes.

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements
This work improves the classification of ALK-negative anaplastic large cell lymphomas (ALCLs) and provides an explanation of the favorable behavior of DUSP22-rearranged ALCL. DUSP22-rearranged ALCL appears to represent a clinically relevant, distinct entity.

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial
Russell and colleagues report longer-term outcomes of the chemotherapy-free treatment with all-trans-retinoic acid (ATRA) and arsenic trioxide for low-risk, intermediate-risk, and high-risk acute promyelocytic leukemia (APL).

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.